The global therapeutic drug monitoring market is expected to reach over USD 3.37 billion by 2024, according to a new report by Grand View Research, Inc. Recent technological advancements in the Point-of-Care (PoC) devices hold considerable transformative promises for the personalized predictive and preventive medicine. Therapeutic Drug Monitoring (TDM) forms a foundational part to the devising of personalized treatment plans for patients; and the advent of PoC diagnostic devices that yield quantitative measurements of the drug concentration plays a pivotal role in supporting the development of the precision medicine field in the healthcare sector. However, the broad application of the PoC devices for patient monitoring is still lagging behind. The presence of this untapped opportunity is one of the high impact rendering drivers for the market growth.
The employment of continuous therapeutic drug and metabolite monitoring in the early phase of the medication regimen, administered post-organ transplantation, forms a major application in the areas of critical care medicine and organ transplantation, which is expected to propel the growth of the therapeutic drug monitoring market over the forecast period. In addition, the imposing burden of diseases, such as epilepsy and cancer, the rising government initiatives, and the presence of high-unmet needs are some of the crucial determinants expected to further favor the emergence of this market.
View
summary of this report @ http://www.grandviewresearch.com/industry-analysis/therapeutic-drug-monitoring-market
U.S. therapeutic drug monitoring market, by product, 2013 - 2024 (USD Million)
·
The consumables segment covered over 65% of the
market share in 2015 as a consequence of the extensive requirement of the
consumables in the research laboratories and due to the repeat purchase of the
kits and reagents.
·
The immunoassay segment held the largest market
share in 2015. The presence of several commercially available immunoassays
combined with their associated benefits including the cost effectiveness and
easy-to-handle nature of the products are the key drivers for the growth of
this segment.
·
The proteomics category is expected to be the
fastest growing technology segment due to the advent of various proteomic
technologies, such as isotope-coded affinity tags, next generation sequencing,
and protein microarray platforms that enable rapid mining of the proteome.
·
The hospital is the largest end-use segment with
a share of over 60% in 2015. In larger hospitals, various underlying
technologies are employed to perform immunoassays; these comprise
chemiluminescence, nephelometry, colorimetry, and fluorescence, which are
available for the testing of a wide ranging drug panel.
·
The drug monitoring for the immunosuppressants
is one of the fastest growing application segments owing to the introduction of
novel TDM point-of-care testing devices for the evaluation of the concentration
of administered immunosuppressants and the complementary metabolites, in order
to achieve a prominent therapeutic effect while preventing drug toxicity events
in patients that have undergone transplantations.
·
In 2015, North America was the highest revenue
generating region with revenue generated over USD 900 million. The rising
number of R&D activities coupled with the high awareness about personalized
therapy is the major determining factor for the large share captured by the
North America region.
·
Few of the leading market players are Roche
Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., Bio-Rad
Laboratories, Inc., Beckman Coulter, Inc., Abbott Laboratories, Inc., Agilent
Technologies, Inc., bioMérieux, Inc., and Alere, Inc. The persistent R&D
efforts are being undertaken along with numerous other strategic endeavors
being adopted by the market players with the objective of enhancing the present
drug monitoring practices and to develop novel technologies.
Browse
more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the therapeutic drug monitoring market on the basis of product, technology, application, end-use, and region:
Therapeutic Drug Monitoring Market, Product Outlook, by Revenue (USD Million, 2013 - 2024)
·
Consumables
·
Equipment
·
Others
Therapeutic Drug Monitoring Market, Technology Outlook, by Revenue
(USD Million, 2013 - 2024)
·
Immunoassays
·
Proteomic technologies
·
Others
Therapeutic Drug Monitoring Market Drug, Class Outlook, by Revenue
(USD Million, 2013 - 2024)
·
Anti-epileptics
·
Antibiotics
·
Immunosuppressants
·
Psychoactive drugs
·
Antiarrhythmic drugs
·
Others
Therapeutic Drug Monitoring Market, End-use Outlook, by Revenue (USD
Million, 2013 - 2024)
·
Hospital labs
·
Private labs
·
Others
Therapeutic Drug Monitoring Market, Regional Outlook, by Revenue
(USD Million, 2013 - 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
·
MEA
o
South Africa
For press release of this report - http://www.grandviewresearch.com/press-release/global-therapeutic-drug-monitoring-market
No comments:
Post a Comment